中国新药杂志

新型抗精神病药SEP-363856

PDF下载

唐金蕾 ¹ , 司淑萍 ² , 翟金国 ¹ , 赵靖平 ³ , 林烁 ¹

中国新药杂志 | 新药述评与论坛 2021,30(8): 685-689

收起

中国新药杂志 |新药述评与论坛 2021 , 30 (8) : 685 -689

新型抗精神病药SEP-363856

全屏

唐金蕾¹, 司淑萍², 翟金国¹, 赵靖平³, 林烁¹

作者信息

¹济宁医学院精神卫生学院，济宁　272067

²济宁市精神病防治院，济宁　272051

³中南大学湘雅二医院　精神卫生研究所，精神病学与精神卫生学湖南省重点实验室，长沙　410011

通讯作者:

翟金国，男，教授，硕士生导师。联系电话：（0537）3165634，E-mail：zhaijinguo@163.com。

作者简介:

唐金蕾，女，硕士研究生，主要从事临床精神病学相关研究。

A novel antipsychotic drug, SEP-363856

Jin-lei TANG¹, Shu-ping SI², Jin-guo ZHAI¹, Jing-ping ZHAO³, Shuo LIN¹

Affiliations

¹School of Mental Health of Jining Medical University, Jining 272067, China

²Jining Mental Hospital, Jining 272051, China

³Mental Health Institute of The Second Xiangya Hospital, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha 410011, China

出版时间: 2021-04-30

文章导航

摘要

收起

SEP-363856是一种新型抗精神病药，确切的作用机制未明，目前研究认为，该药与以往的抗精神病药作用机制不同，它不是通过拮抗多巴胺D₂受体，而是通过激活5-羟色胺1A（5-HT_1A）受体以及痕量胺相关受体1（TAAR1）而发挥药理作用。最近SEP-363856获得美国FDA授予的突破性疗法认定，用于治疗成人精神分裂症。本文对突破性疗法、SEP-363856的药理作用机制、药动学、药物相互作用、临床应用、安全性和耐受性等相关文献进行综述。

关键词

SEP-363856 / 抗精神病药 / 精神分裂症 / 临床应用 / 耐受性

Abstract

收起

SEP-363856 is a novel antipsychotic drug, the exact mechanism of action of which is not clear. At present, it is believed that the mechanism of action of sep-363856 is different from that of previous antipsychotic drugs, it does not play a pharmacological role by antagonizing dopamine D₂ receptor, but by activating 5-hydroxytryptamine 1A (5-HT_1A) receptor and trace amine-associated receptor 1 (TAAR1). Recently, SEP-363856 has received breakthrough therapy designation of the US Food and Drug Administration for the treatment of adult patients with schizophrenia. In this paper, breakthrough therapy designation, the pharmacological mechanism, pharmacokinetics, drug-drug interaction, clinical application, safety and tolerance of SEP-363856 are reviewed.

Key words

SEP-363856 / antipsychotic / schizophrenia / clinical application / tolerance

引用本文

唐金蕾, 司淑萍, 翟金国, 赵靖平, 林烁. 新型抗精神病药SEP-363856. 中国新药杂志, 2021 , 30 (8) : 685 -689 .

Jin-lei TANG, Shu-ping SI, Jin-guo ZHAI, Jing-ping ZHAO, Shuo LIN. A novel antipsychotic drug, SEP-363856[J]. Chinese Journal of New Drugs, 2021 , 30 (8) : 685 -689 .

基金

收起

山东省自然科学基金项目(ZR2017LH036)
山东省医药卫生科技发展计划项目(2015WS0417; 2013WS0329)
山东省高等学校科技计划项目(J14LK56)
济宁医学院教师发展基金(JY2017JS007)
济宁医学院大学生科研项目(JYXS2017KJ012)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

DEDIC N, JONES PG, HOPKINS SC, et al. SEP-363856, a novel psychotropic agent with a unique, non-D receptor mechanism of action[J]. J Pharmacol Exp Ther, 2019, 371(1): 1-14.

[2]

Sunovion and psychogenics announce that SEP-363856 has received FDA breakthrough therapy designation for the treatment of people with schizophrenia[EB/OL]. (2020-03-03). https://www.businesswire.com.

[3]

HERINK MC, IRWIN AN, ZUMACH GM. FDA Breakthrough therapy designation: evaluating the quality of the evidence behind the drug approvals[J]. Pharmacotherapy, 2018, 38(9): 967-980.

[4]

BENZ EJ JR. Breakthrough therapy designation for new drugs[J]. JAMA, 2018, 320(19): 2042.

[5]

PUTHUMANA J, WALLACH JD, ROSS JS. Breakthrough therapy designation for new drugs-reply[J]. JAMA, 2018, 320(19): 2042-2043.

[6]

PUTHUMANA J, WALLACH JD, ROSS JS. Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation[J]. JAMA, 2018, 320(3): 301-303.

[7]

DARROW JJ, AVORN J, KESSELHEIM AS. The FDA treakthrough-drug designation-four years of experience[J]. N Engl J Med, 2018, 378(15): 1444-1453.

[8]

CORRIGAN-CURAY J, MCKEE AE, STEIN P. Breakthrough-therapy designation-an FDA perspective[J]. N Engl J Med, 2018, 378(15): 1457-1458.

[9]

SHERMAN RE, LI J, SHAPLEY S, et al. Expediting drug development-the FDA's new “breakthrough therapy” designation[J]. N Engl J Med, 2013, 369(20): 1877-1880.

[10]

CHRISTIAN SL, BERRY MD. Trace amine-associated receptors as novel therapeutic targets for immunomodulatory disorders[J]. Front Pharmacol, 2018, 9: 680.

[11]

SCHWARTZ MD, CANALES JJ, ZUCCHI R, et al. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases[J]. Expert Opin Ther Targets, 2018, 22(6): 513-526.

[12]

TAKEKITA Y, FABBRI C, KATO M, et al. HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in schizophrenia[J]. J Clin Psychopharmacol, 2015, 35(3): 220-227.

[13]

TAUSCHER J, KAPUR S, VERHOEFF NP, et al. Brain serotonin 5-HT (1A) receptor binding in schizophrenia measured by positron emission tomography and [11C] WAY-100635[J]. Arch Gen Psychiatry, 2002, 59(6): 514-520.

[14]

ESPINOZA S, LIGNANI G, CAFFINO L, et al. TAAR1 modulates cortical glutamate NMDA receptor function[J]. Neuropsychopharmacology, 2015, 40(9): 2217-2227.

[15]

XU Z, LI Q. TAAR agonists[J]. Cell Mol Neurobiol, 2020, 40(2): 257-272.

[16]

SCHWARTZ MD, CANALES JJ, ZUCCHI R, et al. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases[J]. Expert Opin Ther Targets, 2018, 22(6): 513-526.

[17]

司天梅, 陈胜良, 郝伟, 等. 5-HT (1A)受体参与常见精神疾病病理机制及5-HT (1A)受体部分激动剂的潜在治疗效应研究进展[J]. 中国新药与临床杂志, 2018, 37(9): 503-508.

[18]

SCHWARTZ MD, BLACK SW, FISHER SP, et al. Trace amine-associated receptor 1 regulates wakefulness and EEG spectral composition[J]. Neuropsychopharmacology, 2017, 42(6): 1305-1314.

[19]

KOBLAN K, HOPKINS S, JUSTIN K, et al. Efficacy and safety of SEP-363856, a novel non-D2 agent, in the treatment of schizophrenia: a 4-week, randomized, placebo-controlled trial[J]. Eur Neuropsychopharmacol, 2019, 29(Suppl 6): S85-S86.

[20]

ZANIN KA, PATTI CL, SANDAY L, et al. Effects of zolpidem on sedation, anxiety, and memory in the plus-maze discriminative avoidance task[J]. Psychopharmacology (Berl), 2013, 226(3): 459-474.

[21]

HALL-PORTER JM, SCHWEITZER PK, EISENSTEIN RD, et al. The effect of two benzodiazepine receptor agonist hypnotics on sleep-dependent memoryconsolidation[J]. J Clin Sleep Med, 2014, 10(1): 27-34.

[22]

Clinical Trials. A study to evaluate the efficacy and safety of SEP-363856 in acutely psychotic adults with schizophrenia-full text view-clinicaltrials.gov[EB/OL]. (2020-03-03). https://www.clinicaltrials.gov.

[23]

Clinical Trials. An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia-full text view-clinicaltrials.gov[EB/OL]. (2020-03-03). https://www.clinicaltrials.gov.

[24]

Clinical Trials. A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia-full text view-clinicaltrials.gov[EB/OL]. (2020-03-03). https://www.clinicaltrials.gov.

[25]

REVEL FG, MOREAU J-L, GAINETDINOV RR, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity[J]. Proc Natl Acad Sci USA, 2011, 108(20): 8485-8490.

[26]

WICHNIAK A, WIERZBICKA A, WALECKA M, et al. Effects of antidepressants on sleep[J]. Curr Psychiat Rep, 2017, 19(9): 63.

[27]

GOONAWARDENA AV, MORAIRTY SR, DELL R, et al. Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques[J]. Neuropsychopharmacology, 2019, 44(8): 1485-1493.

[28]

LIU J, WU R, LI JX. TAAR1 and psychostimulant addiction[J]. Cell Mol Neurobiol, 2020, 40(2): 229-238.

[29]

JING L, ZHANG Y, LI JX. Effects of the trace amine associated receptor 1 agonist RO5263397 on abuse-related behavioral indices of methamphetamine in rats[J]. Int J Neuropsychopharmacol, 2014, 18(4): 1-7.

[30]

ASIF-MALIK A, HOENER MC. Interaction between the trace amine-associated receptor 1 and the dopamine dreceptor controls cocaine's neurochemical actions[J]. Sci Rep, 2017, 7(1): 13901.

[31]

LIU Y, LIU J, JIAO SR, et al. Serotonin1a receptors in the dorsal hippocampus regulate working memory and long-term habituation in the hemiparkinsonian rats[J]. Behav Brain Res, 2019, 376: 112207.

[32]

DEL BELLO F, AMBROSINI D, BONIFAZI A, et al. Multitarget 1,4-dioxane compounds combining favorable D2-like and 5-HT1A receptorinteractions with potential for the treatment of parkinson's disease or schizophrenia[J]. ACS Chem Neurosci, 2019, 10(5): 2222-2228.

2021年第30卷第8期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-04-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-06-05

基金

山东省自然科学基金项目(ZR2017LH036)

山东省医药卫生科技发展计划项目(2015WS0417; 2013WS0329)

山东省高等学校科技计划项目(J14LK56)

济宁医学院教师发展基金(JY2017JS007)

济宁医学院大学生科研项目(JYXS2017KJ012)

作者信息

¹济宁医学院精神卫生学院，济宁　272067

²济宁市精神病防治院，济宁　272051

³中南大学湘雅二医院　精神卫生研究所，精神病学与精神卫生学湖南省重点实验室，长沙　410011

通讯作者:

翟金国，男，教授，硕士生导师。联系电话：（0537）3165634，E-mail：zhaijinguo@163.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322245672875704587

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT